Phase 3 Clinical Trials With Primary Completion Dates in October 2022
This is a list of Phase 3 trials with primary completion dates in October 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ALID||Allied Corp.||2022-10-01||Phase 3||NCT04172012||Use of Probiotics to Reduce Infections, Death and ESBL Colonisation|
|EYPT||EyePoint Pharmaceuticals, Inc.||2022-10-01||Phase 3||NCT05070728||Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI)|